J

Johnson & Johnson

Makes prescription drugs and medical devices

Head of Market Access

Full-TimeUpdated on 10/15/2026Deadline 10/31/26
No salary listed
Expert
Bachelor's
Taipei City, Taiwan
In Person
Growth & Marketing

About the job

Requirements
  • An advanced degree in pharmacy, life sciences, public health, economics, health economics, business, or a related discipline is required.
  • Significant pharmaceutical or healthcare industry experience is required.
  • Strong experience in pricing, reimbursement, market access, and payer engagement is required.
  • A strong understanding of Taiwan healthcare, National Health Insurance, and reimbursement systems is required.
  • Demonstrated cross-functional leadership experience is required.
  • Experience leading and developing people is required.
  • Strong analytical, communication, and stakeholder-management skills are required.
  • Fluency in English and Chinese is required.
Responsibilities
  • Lead the team in developing and executing pricing and reimbursement strategies for new products, new indications, and existing products.
  • Lead reimbursement planning, submissions, and payer engagement activities to support timely patient access.
  • Oversee development of value dossiers, reimbursement submissions, economic models, and budget impact analyses.
  • Manage product pricing and reimbursement throughout the lifecycle.
  • Ensure market access strategies align with portfolio priorities, launch plans, and business objectives.
  • Identify and manage reimbursement risks, opportunities, and mitigation plans.
  • Provide strategic oversight for health economics, outcomes research, real-world evidence, and other evidence-generation activities that support reimbursement and value demonstration.
  • Identify local evidence needs and ensure their appropriate inclusion in integrated evidence-generation plans.
  • Partner with Medical Affairs and regional and global colleagues to strengthen the evidence base supporting patient access.
  • Lead Market Access input into new product introduction, launch planning, and lifecycle management activities.
  • Ensure access considerations are incorporated into early asset, pre-launch, and launch strategies.
  • Lead development and optimization of patient affordability programs, self-pay solutions, and patient support initiatives.
  • Identify opportunities to address patient access challenges resulting from reimbursement limitations, delays, or affordability barriers.
  • Ensure patient programs are compliant, sustainable, and aligned with company policies.
  • Monitor program effectiveness and recommend improvements to enhance patient impact and organizational value.
  • Monitor developments in healthcare policy, reimbursement systems, and the broader healthcare environment.
  • Assess implications of policy changes and provide recommendations to the organization.
  • Build constructive relationships with healthcare stakeholders relevant to market access and patient access objectives.
  • Participate in appropriate industry associations, working groups, and healthcare forums.
  • Contribute company perspectives through evidence-based engagement and collaboration with relevant stakeholders.
  • Maintain awareness of national and regional developments that may influence future patient access.
  • Monitor developments in private insurance and other evolving healthcare financing approaches.
  • Assess opportunities that may complement existing reimbursement pathways and improve patient access.
  • Support cross-functional evaluation of innovative access models, partnership concepts, and emerging funding mechanisms.
  • Develop business recommendations based on patient value, feasibility, compliance, and strategic fit.
  • Lead, coach, and develop a high-performing Market Access team.
  • Build functional capabilities in pricing, reimbursement, payer engagement, value communication, and evidence generation.
  • Drive employee engagement, accountability, and performance excellence.
  • Develop succession plans and support the growth of future leaders.
  • Foster an inclusive and collaborative team culture.
  • Serve as an active member of the Taiwan Leadership Team.
  • Contribute to business planning, portfolio prioritization, and organizational decision-making.
  • Provide strategic perspectives on healthcare policy, reimbursement trends, and patient access opportunities.
  • Collaborate with cross-functional leaders to support sustainable business growth and improved patient outcomes.
  • Champion the Johnson & Johnson Credo, compliance principles, and organizational culture.
  • Build strong partnerships with regional and global Market Access colleagues and relevant cross-functional partners.
  • Share Taiwan insights, evidence needs, and market developments to support broader access planning.
  • Leverage regional and global best practices where appropriate.
  • Contribute Taiwan expertise to selected regional and cross-market initiatives.
Desired Qualifications
  • Experience in health economics and outcomes research, real-world evidence, or evidence generation.
  • Experience supporting product launches and lifecycle management.
  • Experience with patient affordability or patient support programs.
  • Experience working with regional or global teams.
  • Experience engaging with industry associations or healthcare policy forums.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.

Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.